European Commission closes infringement case for medrep fees in Hungary
This article was originally published in Scrip
The European Commissionhas closed an infringement procedure relating to a Hungarian regulation obliging pharmaceutical companies to pay annual Ft5 million ($30,000) fees for each of their medical representatives. The closure followed Hungary's constitutional court verdict of June 16th, which determined that the fee provision breached the national constitution. However, the court ruled against reclaiming the fees already paid by companies (Scrip Online, June 25th, 2008).
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.